Three-year, naturalistic, mirror-image assessment of adding memantine to the treatment of 30 treatment-resistant patients with bipolar disorder

Journal of Clinical Psychiatry

Volumn 76, Issue 1, 2015, Pages e91-e97

  Serra, Giulia ^a,b,c,d   Koukopoulos, Athanasios ^b   De Chiara, Lavinia ^a,b   Koukopoulos, Alexia E ^a,b   Tondo, Leonardo ^b,c,d,e   Girardi, Paolo ^a,b   Baldessarini, Ross J ^c,d   Serra, Gino ^f  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Lucio Bini Mood Disorders Center   (Italy)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MCLEAN HOSPITAL   (United States)

^e Lucio Bini Mood Disorder Center   (Italy)

^f UNIVERSITY OF SASSARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; LAMOTRIGINE; LITHIUM CARBONATE; LITHIUM SALT; MEMANTINE; MOOD STABILIZER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; VALPROIC ACID; AMINO ACID RECEPTOR BLOCKING AGENT;

ADD ON THERAPY; ADULT; ADVERSE DRUG REACTION; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR MANIA; CLINICAL ASSESSMENT; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG RESPONSE; DSM-IV-TR; ELECTROCONVULSIVE THERAPY; FEMALE; FOLLOW UP; HUMAN; MALE; MEDICAL RECORD REVIEW; MENTAL HOSPITAL; MORBIDITY; NATURALISTIC INQUIRY; OPEN STUDY; OUTPATIENT; PRIORITY JOURNAL; TREATMENT DURATION; DRUG COMBINATION; MIDDLE AGED; PATHOPHYSIOLOGY; TIME; TREATMENT OUTCOME;

ADULT; BIPOLAR DISORDER; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MALE; MEMANTINE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 84925372786     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13m08956     Document Type: Article

References (47)

1. Baldessarini RJ. Chemotherapy in Psychiatry. 3rd ed. New York, NY: Springer Press; 2013.
2. Popovic D, Reinares M, Amann B, et al. Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder. Psychopharmacology (Berl). 2011;213(4):657-667.
3. Vieta E, Günther O, Locklear J, et al. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2011;14(8):1029-1049.
4. Selle V, Schalkwijk S, Vázquez GH, et al. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry. 2014;47(2):43-52.
5. Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013;170(11):1249-1262.
6. Vázquez GH, Tondo L, Undurraga J, et al. Overview of antidepressant treatment of bipolar depression. Int J Neuropsychopharmacol. 2013;16(7):1673-1685.
7. Baldessarini RJ, Salvatore P, Khalsa HM, et al. Morbidity in 303 first-episode bipolar I disorder patients. Bipolar Disord. 2010;12(3):264-270.
8. Ösby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58(9):844-850.
9. Baldessarini RJ, Vieta E, Calabrese JR, et al. Bipolar depression: overview and commentary. Harv Rev Psychiatry. 2010;18(3):143-157.
10. Ferrari AJ, Saha S, McGrath JJ, et al. Health states for schizophrenia and bipolar disorder within the Global Burden of Disease 2010 Study. Popul Health Metr. 2012;10(1):16-23.
11. Noetzli M, Eap CB. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. Clin Pharmacokinet. 2013;52(4):225-241.
12. Olivares D, Deshpande VK, Shi Y, et al. N-methyl-d-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease. Curr Alzheimer Res. 2012;9(6):746-758.
13. D'Aquila PS, Peana AT, Panin F, et al. Reversal of antidepressant-induced dopaminergic behavioural supersensitivity after long-term chronic imipramine withdrawal. Eur J Pharmacol. 2003;458(1-2):129-134.
14. D'Aquila PS, Panin F, Serra G. Chronic valproate fails to prevent imipramine-induced behavioural sensitization to the dopamine D2-like receptor agonist quinpirole. Eur J Pharmacol. 2006;535(1-3):208-211.
15. Demontis F, Cubeddu A, Serra G. Memantine prevents the "bipolar-like behavior" induced by chronic imipramine in rats [abstract]. Poster presented at the 12th International Review of Bipolar Disorders; May 21-23, 2012; Nice, France.
16. Reisberg B, Doody R, Stöffler A, et al Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348(14):1333-1341.
17. Schneider LS, Dagerman KS, Higgins JP, et al. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol. 2011;68(8):991-998.
18. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613-618.
19. Canan F, Ataoglu A. Memantine-related psychotic symptoms in a patient with bipolar disorder. J Clin Psychiatry. 2010;71(7):957.
20. Zdanys K, Tampi RR. A systematic review of off-label uses of memantine for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(6):1362-1374.
21. Sani G, Serra G, Kotzalidis GD, et al. The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence. CNS Drugs. 2012;26(8):663-690.
22. Vidal JS, Lacombe JM, Dartigues JF, et al. Evaluation of the impact of memantine treatment initiation on psychotropics use: a study from the French national health care database. Neuroepidemiology. 2008;31(3):193-200.
23. Wilcock GK, Ballard CG, Cooper JA, et al. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry. 2008;69(3):341-348.
24. Keck PE Jr, Hsu HA, Papadakis K, et al. Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation. Clin Neuropharmacol. 2009;32(4):199-204.
25. Koukopoulos A, Serra G, Koukopoulos AE, et al. The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: findings from a 12-month naturalistic trial. J Affect Disord. 2012;136(1-2):163-166.
26. Serra G, De Chiara L, Koukopoulos A, et al. Antimanic and long-lasting mood stabilizing effect of memantine in bipolar I mood disorder: two case reports. J Clin Psychopharmacol. 2013;33(5):715-717.
27. Serra G, De Chiara L, Manfredi G, et al. Memantine in the management of affective recurrences of bipolar disorders after the discontinuation of long-term lithium treatment: three case histories. Ther Adv Psychopharmacol. 2014;4(1):53-55.
28. Anand A, Gunn AD, Barkay G, et al. Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial. Bipolar Disord. 2012;14(1):64-70.
29. Lee SY, Chen SL, Chang YH, et al. Add-on memantine to valproate treatment increased HDL-C in bipolar II disorder. J Psychiatr Res. 2013;47(10):1343-1348.
30. Spearing MK, Post RM, Leverich GS, et al. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73(3):159-171.
31. Koukopoulos A, Reginaldi D, Tondo L, et al. Course sequences in bipolar disorder: depressions preceding or following manias or hypomanias. J Affect Disord. 2013;151(1):105-110.
32. Tondo L, Isacsson G, Baldessarini RJ. Suicidal behaviour in bipolar disorder: risk and prevention. CNS Drugs. 2003;17(7):491-511.
33. Tondo L, Baldessarini RJ, Vázquez GH, et al. Clinical responses to antidepressants among 1036 acutely depressed patients with bipolar or unipolar major affective disorders. Acta Psychiatr Scand. 2013;127(5):355-364.
34. Grant JE, Odlaug BL, Mooney M, et al. Open-label pilot study of memantine in the treatment of compulsive buying. Ann Clin Psychiatry. 2012;24(2):119-126.
35. Ghaleiha A, Asadabadi M, Mohammadi MR, et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol. 2013;16(4):783-789.
36. Zarate CA Jr, Singh JB, Quiroz JA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 2006;163(1):153-155.
37. Smith EG, Deligiannidis KM, Ulbricht CM, et al. Antidepressant augmentation using the N-methyl-d-aspartate antagonist memantine: randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2013;74(10):966-973.
38. Nugent AC, Diazgranados N, Carlson PJ, et al. Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. Bipolar Disord. 2014;16(2):119-128.
39. Kukopulos A, Reginaldi D. Does lithium prevent depressions by suppressing manias? Int Pharmacopsychiatry. 1973;8(3):152-158.
40. Koukopoulos A, Ghaemi SN. The primacy of mania: a reconsideration of mood disorders. Eur Psychiatry. 2009;24(2):125-134.
41. Berk M, Dodd S. Kauer-Sant'Anna M, et al. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand. 2007;116(suppl 434):41-49.
42. Cousins DA, Butts K, Young AH. The role of dopamine in bipolar disorder. Bipolar Disord. 2009;11(8):787-806.
43. Duman RS. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med. 2004;5(1):11-25.
44. La Spada AR. Memantine strikes the perfect balance. Nat Med. 2009;15(12):1355-1356.
45. Ongür D, Jensen JE, Prescot AP, et al. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol Psychiatry. 2008;64(8):718-726.
46. Gao Y, Payne RS, Schurr A, et al. Memantine reduces mania-like symptoms in animal models. Psychiatry Res. 2011;188(3):366-371.
47. Atmaca M, Yildirim H. Altered neurochemical ingredient of hippocampus in patients with bipolar depression. Depress Res Treat. 2012;2012:485249.